Contacts

MedinCell announces the great success of its capital increase and raises 15.6 M€

June 16, 2020

Strong demand enabling the contemplated size of the transaction to be significantly increased from 11 M€ to 15.6 M€ (+42%)

Major support from French and international shareholders and investors

Additional resources to finance the development of the product portfolio based on BEPO® technology combined with already approved and widely used active ingredients

Increased financial flexibility enabling the Company to achieve its strategic objectives and cover its working capital requirements until the second half of 2022 ; at this time MedinCell should already be receiving royalty revenues from the sale of the first products based on the BEPO® technology

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.